TNFRSF12A and malignant colon neoplasm: An application of GSIs to enhance surface Fn14 levels may also be considered when agonistic Fn14 antibodies, such as BIIB039, are used to stimulate antiproliferative signaling of Fn14 to reduce tumor growth, for example in xenograft models of colon cancer and gastric tumors (Michaelson et al, 2011).